US 11,655,299 B2
Antibodies against human and canine IL-13RA2
Waldemar Debinski, Winston-Salem, NC (US); and Denise Mazess Herpai, Winston-Salem, NC (US)
Assigned to Wake Forest University Health Sciences, Winston-Salem, NC (US)
Filed by Wake Forest University Health Sciences, Winston-Salem, NC (US)
Filed on May 5, 2020, as Appl. No. 16/866,736.
Application 16/866,736 is a division of application No. 15/835,566, filed on Dec. 8, 2017, granted, now 10,676,529.
Application 15/835,566 is a division of application No. 14/776,356, granted, now 9,868,788, issued on Jan. 16, 2018, previously published as PCT/US2014/027254, filed on Mar. 14, 2014.
Claims priority of provisional application 61/788,312, filed on Mar. 15, 2013.
Prior Publication US 2020/0299394 A1, Sep. 24, 2020
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); G01N 33/58 (2006.01); G01N 33/60 (2006.01); A61K 47/68 (2017.01); A61K 49/00 (2006.01); C12N 9/00 (2006.01); A61K 47/69 (2017.01); A61K 39/00 (2006.01)
CPC C07K 16/2866 (2013.01) [A61K 39/3955 (2013.01); A61K 47/6813 (2017.08); A61K 47/6829 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6911 (2017.08); A61K 49/0004 (2013.01); C12N 9/93 (2013.01); G01N 33/58 (2013.01); G01N 33/60 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C12Y 603/01004 (2013.01)] 20 Claims
 
1. A method of detecting a cancer in a subject in need thereof, said method comprising:
administering to said subject an antibody that specifically binds an epitope within amino acids spanning the extracellular portion of human IL-13RA2, wherein said antibody is coupled to a detectable group, in an amount effective to detect said antibody; and
detecting said detectable group, to thereby detect the cancer in the subject,
wherein said epitope is within amino acids of SEQ ID NO: 1 (Peptide 1); SEQ ID NO: 2 (Peptide 2); or SEQ ID NO: 3 (Peptide 3),
wherein said antibody comprises a variable light chain amino acid sequence of SEQ ID NO:8 or at least 95% identity thereto, and a variable heavy chain amino acid sequence of SEQ ID NO:10 or at least 95% identity thereto, and
wherein said antibody specifically binds to both human and canine IL-13RA2.